Daewoong Pharmaceutical
Daewoong Pharmaceutical Co., Ltd., commonly referred to as Daewoong, is a leading South Korean pharmaceutical company headquartered in Incheon, South Korea. Established in 1945, Daewoong has made significant strides in the pharmaceutical industry, focusing on research and development, manufacturing, and marketing of innovative medicines. The company operates extensively across Asia, Europe, and the Americas, with a diverse portfolio that includes prescription drugs, over-the-counter products, and biopharmaceuticals. Notable for its commitment to innovation, Daewoong has developed unique therapies in areas such as gastroenterology, neurology, and endocrinology. With a strong market position, Daewoong has achieved several milestones, including the successful launch of its biosimilar products, which have garnered recognition for their quality and efficacy. As a forward-thinking organisation, Daewoong Pharmaceutical continues to contribute to global health advancements.
DitchCarbon Score
How does Daewoong Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Daewoong Pharmaceutical's score of 30 is higher than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Daewoong Pharmaceutical's reported carbon emissions
In 2024, Daewoong Pharmaceutical reported total carbon emissions of approximately 32,000,000 kg CO2e, comprising about 9,675,000 kg CO2e from Scope 1 and about 23,296,000 kg CO2e from Scope 2 emissions. This marks a slight decrease from 2023, where emissions were about 34,000,000 kg CO2e, with Scope 1 at approximately 10,184,000 kg CO2e and Scope 2 at around 24,522,000 kg CO2e. Over the past few years, Daewoong has demonstrated a commitment to reducing its carbon footprint, although specific reduction targets or initiatives have not been disclosed. The company has not reported any Scope 3 emissions, indicating a focus on direct and indirect emissions from its operations and energy use. Daewoong Pharmaceutical's emissions data is not cascaded from any parent company, and all figures are sourced directly from Daewoong Pharmaceutical Co., Ltd. The company continues to monitor and report its emissions as part of its sustainability efforts, aligning with industry standards for transparency and accountability in climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | - | 0,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 2 | 35,843,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Daewoong Pharmaceutical is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
